3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Phase 3
1
Phase 2
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
85
Lymphoma, Follicular
18
Recurrence
11
Lymphoma, Large B-Cell, Diffuse
11
Neoplasms, Plasma Cell
8
Lymphoma
7
Lymphoma, B-Cell, Marginal Zone
6
Lymphoma, Non-Hodgkin
5
Neoplasms
4
Lymphoma, Mantle-Cell
4
Hematologic Diseases
4
Smoldering Multiple Myeloma
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Disease Progression
3
Paraproteinemias
2
Myelodysplastic Syndromes
2
Disease
2
Anemia
2
Sezary Syndrome
1
Prostatic Neoplasms
1
Polycythemia Vera
1
Plasmacytoma
1
Neoplasm Metastasis
1
Mycosis Fungoides
1
Melanoma
1
Lymphoproliferative Disorders
1
Lymphoma, T-Cell, Cutaneous
1
Limb-girdle muscular dystrophy, type 2C
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Interventions
Dexamethasone
2
daratumumab
1
Lenalidomide
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Plasmacytoma
×
Lenalidomide
×
Clear all
NCT02544308
2022-12-23
IDRIS
University College, London
Phase 3
Active not recruiting
36 enrolled